Bruce Robinson (endocrinologist)

Bruce Robinson is an Australian endocrinologist renowned for his research and clinical contributions to the field of thyroid cancer, particularly medullary thyroid carcinoma (MTC). He is a leading figure in the identification of the RET proto-oncogene and its role in hereditary MTC syndromes such as Multiple Endocrine Neoplasia type 2 (MEN 2).

Robinson's work has been instrumental in understanding the genetic basis of these cancers and developing strategies for early diagnosis and treatment. His research team has contributed significantly to the understanding of genotype-phenotype correlations in RET-related MTC, allowing for more personalized risk assessment and management of affected individuals and families.

He has been involved in the development and implementation of national and international guidelines for the management of thyroid cancer, including recommendations for genetic screening and prophylactic thyroidectomy in individuals carrying RET mutations.

Robinson has held numerous academic and clinical leadership positions in Australia, contributing significantly to the advancement of endocrinology and medical research. He is widely published in peer-reviewed journals and is frequently invited to speak at international conferences on thyroid cancer and related topics. His work has had a significant impact on the clinical care of patients with MTC and related inherited syndromes.